ClinicalTrials.gg
CompletedNCT00362934Updated Jul 8, 2009

Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin

A Phase 3 interventional study of fenofibrate / simvastatin and Atorvastatin in Hyperlipidemia, sponsored by Solvay Pharmaceuticals. Completed at 68 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-07-08.

Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
516
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing fenofibrate in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Fenofibrate · Hyperlipidemias.

Enrollment
3rd of 14
516 · median 178
Started
2006
with 1 other
Phase 3
7 of 14
none open now
Registered
8th of 14
by date
Lead sponsor
4 of 14
Solvay Pharmaceuticals

Among the 14 studies testing fenofibrate in Hyperlipidemias, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 7 in phase 3, and was the 8th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 14 studies testing fenofibrate in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About fenofibrate

Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing fenofibrate in Hyperlipidemias as a file.
02

Study summary

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to compare the efficacy and safety of combining fenofibrate and simvastatin versus atorvastatin monotherapy in patients with mixed hyperlipidemia at risk of cardiovascular diseases.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

Keywords

  • Hyperlipidemia Combined
  • efficacy combination fenofibrate simvastatin versus atorvastatin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mixed dyslipidemia.

Exclusion criteria

Exclusion Criteria:

  • Known to fenofibrates or simvastatin or atorvastatin
  • Pregnant or lactating women
  • to fenofibrate or simvastatin or atorvastatin
  • Unstable or severe cardiac disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
516 participants (actual)

Study arms

  • Experimental
    1

    Drug: fenofibrate / simvastatin

  • Active comparator
    2

    Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change from baseline to 12 weeks of treatment in Triglycerides

    Time frame: 12 weeks

  2. Percent change from baseline to 12 weeks of treatment in HDL-C

    Time frame: 12 weeks

  3. Percent change from baseline to 12 weeks of treatment in LDL-C

    Time frame: 12 weeks

Secondary outcomes

  1. Percent change from baseline to 12 weeks of treatment in Triglycerides

    Time frame: 24 weeks

  2. Percent change from baseline to 12 weeks of treatment in HDL-C

    Time frame: 24 weeks

  3. Percent change from baseline to 12 weeks of treatment in LDL-C

    Time frame: 24 weeks

07

Study locations

68 sites
  • Site 501
    Haskovo, Bulgaria
  • Site 505
    Pleven, Bulgaria
  • Site 503
    Plovdiv, Bulgaria
  • Site 506
    Plovdiv, Bulgaria
  • Site 500
    Sofia, Bulgaria
  • Site 502
    Sofia, Bulgaria
  • Site 504
    Sofia, Bulgaria
  • Site 507
    Sofia, Bulgaria
  • Site 509
    Sofia, Bulgaria
  • Site 511
    Sofia, Bulgaria
  • Site 508
    Varna, Bulgaria
  • Site 510
    Varna, Bulgaria
  • Site 109
    Chrudim, Czech Republic
  • Site 117
    Havirov, Czech Republic
  • Site 101
    Olomouc, Czech Republic
  • Site 114
    Olomouc, Czech Republic
  • Site 116
    Ostrava, Czech Republic
  • Site 107
    Pardubice, Czech Republic
  • Site 111
    Pardubice, Czech Republic
  • Site 113
    Plzen, Czech Republic
  • Site 108
    Praha 1, Czech Republic
  • Site 100
    Praha 2, Czech Republic
  • Site 104
    Praha 5, Czech Republic
  • Site 110
    Praha 6, Czech Republic
  • Site 115
    Praha, Czech Republic
  • Site 103
    Teplice, Czech Republic
  • Site 106
    Trutnov, Czech Republic
  • Site 118
    Unicov, Czech Republic
  • Site 102
    Usti nad Orlici, Czech Republic
  • Site 203
    Berlin, Germany
  • Site 204
    Bochum, Germany
  • Site 205
    Dresden, Germany
  • Site 206
    Gorlitz, Germany
  • Site 202
    Hamburg, Germany
  • Site 208
    Karlsruhe, Germany
  • Site 207
    Leipzig, Germany
  • Site 201
    Magdeburg, Germany
  • Site 209
    Nuernberg, Germany
  • Site 200
    Unterschneidheim, Germany
  • Site 301
    Banska Bystrica, Slovakia
  • Site 307
    Bratislava, Slovakia
  • Site 310
    Bratislava, Slovakia
  • Site 311
    Bratislava, Slovakia
  • Site 312
    Bratislava, Slovakia
  • Site 309
    Dolny kubin, Slovakia
  • Site 302
    Kosice, Slovakia
  • Site 305
    Lucenec, Slovakia
  • Site 306
    Nitra, Slovakia
  • Site 304
    Nove Zamky, Slovakia
  • Site 308
    Presov, Slovakia
  • Site 303
    Vrable, Slovakia
  • Site 300
    Zilina, Slovakia
  • Site 416
    Donetsk, Ukraine
  • Site 401
    Kharkov, Ukraine
  • Site 412
    Kiev, Ukraine
  • Site 402
    Kyiv, Ukraine
  • Site 404
    Kyiv, Ukraine
  • Site 408
    Kyiv, Ukraine
  • Site 410
    Kyiv, Ukraine
  • Site 414
    Lutsk, Ukraine
  • Site 406
    Lviv, Ukraine
  • Site 407
    Odessa, Ukraine
  • Site 409
    Odessa, Ukraine
  • Site 411
    Odessa, Ukraine
  • Site 405
    Simferopol, Ukraine
  • Site 413
    Uzhorod, Ukraine
  • Site 400
    Vinnitsa, Ukraine
  • Site 415
    Zaporozhye, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2006
First posted
Aug 15, 2006
Start
Oct 2006
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Last update
Jul 8, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00362934
First posted
Aug 15, 2006
Start date
Oct 2006
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Jul 8, 2009

Study contacts

Global Clinical Director Solvay
study director · Solvay Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fenofibrate · Simvastatin

Start the discussion